It is up to Cytodyn management to overcome obstacles. Does not matter whether those challenges were put in place by former management, Amarex, the FDA ...

Thus far little has been completed to build shareholder value, yet an exorbitant amount of money has been spent and the company has extreme debt.

Hoping for something this week to show that is changing.